RR and AR of second malignancy by overall treatment exposure in 961 patients with more than 10 years of potential follow-up
| Initial therapy . | No. . | PY . | O . | E . | RR . | (95% CI) . | AR . |
|---|---|---|---|---|---|---|---|
| All patients | |||||||
| CMT8-150 | 296 | 4 046 | 53 | 8.6 | 6.18-151 | (4.7, 8.0) | 109.7 |
| RT | 665 | 10 302 | 109 | 26.9 | 4.08-151 | (3.4, 4.9) | 79.6 |
| Nonrelapsed cases | |||||||
| CMT | 256 | 3 739 | 48 | 8.2 | 5.98-152 | (4.2, 7.7) | 106.5 |
| RT | 492 | 7 997 | 79 | 21.2 | 3.78-152 | (3.0, 4.6) | 72.3 |
| Relapsed cases | |||||||
| Relapsed after CMT | 40 | 307 | 5 | 0.4 | 11.38-153 | (3.7, 26.3) | 148.2 |
| Relapsed after RT | 173 | 2 305 | 30 | 5.8 | 5.28-153 | (3.5, 7.2) | 105.1 |
| Initial therapy . | No. . | PY . | O . | E . | RR . | (95% CI) . | AR . |
|---|---|---|---|---|---|---|---|
| All patients | |||||||
| CMT8-150 | 296 | 4 046 | 53 | 8.6 | 6.18-151 | (4.7, 8.0) | 109.7 |
| RT | 665 | 10 302 | 109 | 26.9 | 4.08-151 | (3.4, 4.9) | 79.6 |
| Nonrelapsed cases | |||||||
| CMT | 256 | 3 739 | 48 | 8.2 | 5.98-152 | (4.2, 7.7) | 106.5 |
| RT | 492 | 7 997 | 79 | 21.2 | 3.78-152 | (3.0, 4.6) | 72.3 |
| Relapsed cases | |||||||
| Relapsed after CMT | 40 | 307 | 5 | 0.4 | 11.38-153 | (3.7, 26.3) | 148.2 |
| Relapsed after RT | 173 | 2 305 | 30 | 5.8 | 5.28-153 | (3.5, 7.2) | 105.1 |
PY indicates person-years; O, observed; E, expected; RR, relative risk; CI, confidence interval; AR, absolute excess risk; CMT, combined modality therapy; RT, radiation therapy.
90% of patients who received CMT were treated with alkylating agent–containing regimens.
P = .015.
P = .016.
P = .19.